Pfizer Inc. to buy cancer drug company for $14billion

Pfizer Inc said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company’s growing oncology roster. This move has struck out numerous other bidders. Medivation shares were up 20 percent at $80.43 in midday trading, just shy of the offer price… Read More Pfizer Inc. to buy cancer drug company for $14billion